BioNTech to highlight clinical results from CAR T program

By The Science Advisory Board staff writers

November 1, 2021 -- BioNTech plans to highlight new clinical data from a phase I/II trial of its BNT211 CAR T-cell therapy candidate at the Society for Immunotherapy of Cancer meeting in Washington, DC, on November 12.

BNT211 is an autologous CAR T-cell therapy that targets oncofetal antigen claudin 6 (CLDN6), according to the company. BNT211 is currently in trials for assessment as a monotherapy, as well as in combination with a CLDN6 mRNA-based vaccine (CARVac), for the treatment of relapsed or refractory advanced solid tumors, BioNTech said.


Copyright © 2021 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.